DexCom Faces Wave of Securities Class Actions Over FDA-Faulted CGM Changes
Investor law firms are urging shareholders to seek lead-plaintiff roles before late-December filing deadlines tied to steep stock drops and device safety findings.
Overview
- DexCom is the target of multiple federal securities class actions alleging it misled investors about the safety, reliability, and claimed enhancements of its G6 and G7 glucose monitors.
- The suits cite an FDA Warning Letter made public in March 2025 that said DexCom modified sensors without approval, reduced accuracy, and increased health risks.
- A key case is pending in the Southern District of New York under the caption Prime v. DexCom, Inc., No. 1:25-cv-08912.
- Notices from firms including Bleichmar Fonti & Auld, Rosen, Lowey Dannenberg, Wolf Haldenstein, Kessler Topaz, Levi & Korsinsky, and Robbins LLP set lead-plaintiff deadlines around December 26–29, 2025.
- Complaints also reference a September 2025 Hunterbrook Research report alleging hospitalizations and deaths linked to G7 inaccuracies and describing a culture prioritizing margins over safety.